• AgraFlora Organics (CSE:AGRA) subsidiary, Farmako, has submitted applications for two essential licenses in Germany
  • Farmako has applied for EU Good Manufacturing Practice (EU GMP) certification, and Manufacturing and Import Authorisation (MIA)
  • The company expects that both licensing processes will be complete by the summer this year
  • AgraFlora Organics (AGRA) is down 8.33 per cent, and is currently trading at 5.5 cents per share

Farmako GmbH, a subsidiary of cannabis company AgraFlora Organics (CSE:AGRA), has applied for two certifications and licenses in Germany.

The company has submitted application documents to regional German authorities for EU GMP certification and Manufacturing and Import Authorisation (MIA) licensing.

An EU GMP is a European Union Good Manufacturing Practice certification. The EU GMP ensures that a medical manufacturers’ production processes comply with regulatory standards.

Farmako already has a number of certifications and licenses, including an EU GDP (Good Distribution Practice) certification. The company also has a wholesale authorisation (WDA), and a controlled drug license under Germany’s Controlled Drug Law. 

Farmako is also one of the rare German companies with special authorisation to distribute medical cannabis flowers that have undergone ionising radiation treatment. 

If Farmako obtains the MIA and GMP certification, it can start importing medical cannabis products from outside of the European Economic Community (EEC). 

Farmako CEO, Katrin Eckmans, commented on the necessity of the licenses.

“Germany has the highest standards in the world to ensure the safety of patients, and to bolster trust that patients, physicians and pharmacists have in the program.

“As a result, it is very challenging for new businesses to enter the market. This has created a limited amount of medical cannabis supply for the German marketplace.

“Our submission is a critical step towards obtaining the required EU GMP certification and MIA that will allow Farmako to greatly increase the supply – and thus the available portfolio range of high quality medical cannabis products available to German patients,” she said.

Farmako expects that processing of both licenses will be complete by the summer this year.

AgraFlora Organics (AGRA) is down 8.33 per cent, and is trading at 5.5 cents per share as of 2:17pm EST.

More From The Market Online

The Market Online’s Weekly Cannabis Report – April 19, 2024

Cannabis news this week: Canopy Growth shareholders overwhelmingly voted to approve a new class of exchangeable shares.

Buzz on the Bullboards: Challenges amid inflation and geopolitical tensions

Canadian and U.S. stock markets grapple with a host of challenges, from surging inflation data to escalating tensions in the Middle East.

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.
Canopy Growth - CEO, David Klein.

Canopy Growth shareholders approve Canopy USA asset strategy

After rearranging its capital structure, Canopy Growth (TSX:WEED) will be closer to establishing a U.S.-based multi-state operator.